- Lunsumio combined with lenalidomide shows promise in relapsed or refractory follicular lymphoma.
- Subcutaneous Lunsumio plus Polivy offers chemotherapy-free potential for R/R large B-cell lymphoma.
- Data presented at the 67th American Society of Hematology Annual Meeting, December 2025.
Study Overview
Roche has presented new data on Lunsumio® (mosunetuzumab) at the 67th American Society of Hematology Annual Meeting. The data highlights its potential in earlier treatment lines for various types of lymphoma.
Combination with Lenalidomide
The combination of Lunsumio with lenalidomide may provide an effective treatment for relapsed or refractory follicular lymphoma. This is based on initial data from a single-arm US cohort of the phase III CELESTIMO study.
Subcutaneous Lunsumio and Polivy
Data from the combination of subcutaneous Lunsumio with Polivy reinforce its potential as an outpatient, chemotherapy-free treatment for people with relapsed or refractory large B-cell lymphoma.
Implications for Lymphoma Treatment
The results underscore the potential of innovative Lunsumio combination regimens to improve outcomes for more lymphoma patients earlier in their disease progression.
